Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

June 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

June 01, 2024

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

News Daily News

New FDA Indication Opens Up Use of Sacubitril/Valsartan in HFpEF

February 16, 2021

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.